.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Clinical Scenarios: Treatment Decisions in Non-Small Cell Lung Cancer

EP. 1: Dr. Herbst on Considerations for Frontline Immunotherapy in NSCLC

September 1st 2022

Roy S. Herbst, MD, PhD, discusses considerations for frontline immunotherapy in non–small cell lung cancer.

EP. 2: Dr. Langer on the Benefit of Atezolizumab Following Progression in Advanced NSCLC

September 1st 2022

Corey J. Langer, MD, discusses the benefit observed with the continued treatment of atezolizumab following disease progression in patients with advanced non–small cell lung cancer.

EP. 3: Treatment Decisions in Non-Small Cell Lung Cancer

October 7th 2022

In a recent OncLive® Scientific Interchange, Roy S. Herbst, MD, PhD served as the moderator for a discussion on n using immunotherapy (IO) and targeted therapeutics in patients with NSCLC, to discuss factors impacting therapeutic selection and sequencing strategies in NSCLC, and to evaluate and obtain feedback on the evolving landscape of immunotherapy–based regimens in treating the disease.